Hey there! Welcome!
Get updated on
Select Speciality
Top Picks
12 Oct, 26
AAP 2026
These studies presented at AAP 2026 highlight advances in pediatric gastroenterology and surgery through improved disease surveillance, feeding and swallowing strategies, surgical optimization, microbiome-based therapies, and emerging treatments for refractory inflammatory bowel disease.
12 Oct, 26AAP 2026
These studies presented at AAP 2026 highlight how targeted quality-improvement strategies, standardized follow-up care, and early risk stratification can optimize pediatric emergency and critical care outcomes, while severe cases underscore the need for advanced multidisciplinary management.
27 Oct, 26Diabetes Obes Metab.
- The study demonstrated a significant nonlinear association between eGFR & all-cause mortality in 595 DFU patients
- Mortality increased markedly with eGFR <45 mL/min/1.73 m², adjusted HRs were 2.59 for eGFR 30-<45 & 4.67 for eGFR <30 vs ≥60 mL/min/1.73 m²
- Advanced age, lower BMI, & hypoalbuminemia independently predicted mortality
- Routine eGFR testing supports early DFU risk assessment.
12 Oct, 26BMJ Diabetes Open Re...
- Among 182 biopsy-proven DKD patients, 22.5% had SGHS (eGFRcys/eGFRcr <0.60), eGFRcys/eGFRcr ratio predicted CVD better than conventional renal markers (AUC 0.730)
- SGHS was independently associated with prevalent CVD (OR 9.27) & increased risk of DKD progression during 30.1 mths of follow-up (HR 2.65)
- The eGFRcys/eGFRcr ratio, an easily obtainable parameter, may be a valuable risk assessment tool in DKD patients.
12 Oct, 26Respir Med
- In this prospective ECOPD study, any mild-to-severe exacerbation was associated with significantly faster lung-function decline, including greater annual reductions in postbronchodilator FEV₁ and FEV₁% predicted
- Similar trends occurred in mild-to-moderate COPD and GOLD 2025 A patients
- These findings highlight that even mild exacerbations are clinically important and should be considered in COPD management.
8 Oct, 26ESC Heart Fail.
- Amongst 109,909 HFpEF patients, 26%-70% had WHO-defined anemia
- Anemia was independently associated with higher all-cause mortality: aHR 1.49 (95% CI 1.35-1.66; I²=85%) for LVEF ≥40% & aHR 1.41 (95% CI 1.26-1.57; I²=83%) for LVEF ≥50%
- Each 1 g/dL decrease in hemoglobin increased mortality risk by 17% (aHR 1.17)
- Anemia may improve risk tratification in HFpEF; trials are warranted to confirm the finding.
29 Sep, 26
Featured
26 Oct, 26
26 Oct, 26
26 Oct, 26
